Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 4/2017

01-12-2017 | Fungal Genomics and Pathogenesis (S Shoham, Section Editor))

Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients

Authors: Palash Samanta, M. Hong Nguyen

Published in: Current Fungal Infection Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

Transplant patients are at high risk for invasive pulmonary aspergillosis, and the associated mortality is high. The purpose of this study is to review the pathogenesis of invasive pulmonary aspergillosis (IPA) in transplant patients.

Recent Findings

The pathogenesis of aspergillosis is multifactorial and results from a complex interplay between the pathogen and host. It is well recognized that Aspergillus causes IPA in immunocompromised patients. Recent studies have shown that Aspergillus might also cause diseases likely attributed to an unmodulated immune response in certain transplant recipients such as bronchopulmonary aspergillosis or bronchiolitis obliterans syndrome in lung transplant recipients.

Summary

This review focuses on two crucial axes of the damage response framework applicable to aspergillosis: (1) Aspergillus virulence attributes that enable it to survive and proliferate in the host (thermotolerance, stress and hypoxic response, secretion of secondary metabolites) and (2) host response with specific focus on innate immunity and angiogenesis.
Literature
1.
2.
McCormick A, Loeffler J, Ebel F. Aspergillus fumigatus: contours of an opportunistic human pathogen. Cell Microbiol. 2010;12(11):1535–43.CrossRefPubMed
3.
Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat rev Microbiol. 2003;1(1):17–24.CrossRefPubMed
4.
•• Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect dis. 2016;63(4):e1–e60. This is a current IDSA guideline on diagnosis and management of aspergillosis. CrossRefPubMedPubMedCentral
5.
Schmitt HJ, Blevins A, Sobeck K, Armstrong D. Aspergillus species from hospital air and from patients. Mycoses. 1990;33(11–12):539–41.PubMed
6.
Hospenthal DR, Kwon-Chung KJ, Bennett JE. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol. 1998;36(3):165–8.CrossRefPubMed
7.
Panagopoulou P, Filioti J, Petrikkos G, Giakouppi P, Anatoliotaki M, Farmaki E, et al. Environmental surveillance of filamentous fungi in three tertiary care hospitals in Greece. J Hosp Infect. 2002;52(3):185–91.CrossRefPubMed
8.
Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect dis Clin N am. 2002;16(4):875–94. vi CrossRef
9.
Augustowska M, Dutkiewicz J. Variability of airborne microflora in a hospital ward within a period of one year. Ann Agric Environ med. 2006;13(1):99–106.PubMed
10.
Xavier MO, Sales Mda P, Camargo Jde J, Pasqualotto AC, Severo LC. Aspergillus niger causing tracheobronchitis and invasive pulmonary aspergillosis in a lung transplant recipient: case report. Rev Soc Bras med Trop. 2008;41(2):200–1.CrossRefPubMed
11.
12.
Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol. 2010;150(4):406–17.PubMed
13.
Alekseeva L, Huet D, Femenia F, Mouyna I, Abdelouahab M, Cagna A, et al. Inducible expression of beta defensins by human respiratory epithelial cells exposed to Aspergillus fumigatus organisms. BMC Microbiol. 2009;9:33.CrossRefPubMedPubMedCentral
14.
Agerberth B, Grunewald J, Castanos-Velez E, Olsson B, Jornvall H, Wigzell H, et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care med. 1999;160(1):283–90.CrossRefPubMed
15.
Schnapp D, Harris A. Antibacterial peptides in bronchoalveolar lavage fluid. Am J Respir Cell Mol Biol. 1998;19(3):352–6.CrossRefPubMed
16.
Travis SM, Conway BA, Zabner J, Smith JJ, Anderson NN, Singh PK, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol. 1999;20(5):872–9.CrossRefPubMed
17.
Bellanger AP, Millon L, Khoufache K, Rivollet D, Bieche I, Laurendeau I, et al. Aspergillus fumigatus germ tube growth and not conidia ingestion induces expression of inflammatory mediator genes in the human lung epithelial cell line A549. J med Microbiol. 2009;58(Pt 2):174–9.CrossRefPubMed
18.
Madan T, Eggleton P, Kishore U, Strong P, Aggrawal SS, Sarma PU, et al. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun. 1997;65(8):3171–9.PubMedPubMedCentral
19.
Madan T, Kishore U, Singh M, Strong P, Hussain EM, Reid KB, et al. Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. Infect Immun. 2001;69(4):2728–31.CrossRefPubMedPubMedCentral
20.
Madan T, Reid KB, Clark H, Singh M, Nayak A, Sarma PU, et al. Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. Mol Immunol. 2010;47(10):1923–30.CrossRefPubMed
21.
22.
Singh M, Madan T, Waters P, Sonar S, Singh SK, Kamran MF, et al. Therapeutic effects of recombinant forms of full-length and truncated human surfactant protein D in a murine model of invasive pulmonary aspergillosis. Mol Immunol. 2009;46(11–12):2363–9.CrossRefPubMed
23.
Wasylnka JA, Moore MM. Aspergillus fumigatus conidia survive and germinate in acidic organelles of A549 epithelial cells. J Cell Sci. 2003;116(Pt 8):1579–87.CrossRefPubMed
24.
Berkova N, Lair-Fulleringer S, Femenia F, Huet D, Wagner MC, Gorna K, et al. Aspergillus fumigatus conidia inhibit tumour necrosis factor- or staurosporine-induced apoptosis in epithelial cells. Int Immunol. 2006;18(1):139–50.CrossRefPubMed
25.
Tomee JF, Wierenga AT, Hiemstra PS, Kauffman HK. Proteases from Aspergillus fumigatus induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines. J Infect dis. 1997;176(1):300–3.CrossRefPubMed
26.
Amitani R, Murayama T, Nawada R, Lee WJ, Niimi A, Suzuki K, et al. Aspergillus culture filtrates and sputum sols from patients with pulmonary aspergillosis cause damage to human respiratory ciliated epithelium in vitro. Eur Respir J. 1995;8(10):1681–7.CrossRefPubMed
27.
Amitani R, Taylor G, Elezis EN, Llewellyn-Jones C, Mitchell J, Kuze F, et al. Purification and characterization of factors produced by Aspergillus fumigatus which affect human ciliated respiratory epithelium. Infect Immun. 1995;63(9):3266–71.PubMedPubMedCentral
28.
Ben-Ami R. Angiogenesis at the mold-host interface: a potential key to understanding and treating invasive aspergillosis. Future Microbiol. 2013;8(11):1453–62.CrossRefPubMed
29.
• Ben-Ami R, Albert ND, Lewis RE, Kontoyiannis DP. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect dis. 2013;207(7):1066–74. This murine study suggests that vasculogenic pathways are unexplored targets for the treatment of invasive pulmonary aspergillosis. CrossRefPubMedPubMedCentral
30.
Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood. 2009;114(26):5393–9.CrossRefPubMedPubMedCentral
31.
Shibuya K, Ando T, Hasegawa C, Wakayama M, Hamatani S, Hatori T, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother. 2004;10(3):138–45.CrossRefPubMed
32.
Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, Metzler LJ, et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog. 2008;4(11):e1000200.CrossRefPubMedPubMedCentral
33.
Kamai Y, Chiang LY, Lopes Bezerra LM, Doedt T, Lossinsky AS, Sheppard DC, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol. 2006;44(Suppl 1):S115–7.CrossRefPubMed
34.
Kontoyiannis RB-AaDP. Aspergillosis: from diagnosis to prevention. Editors: Comarú Pasqualotto, Alessandro (Ed) 2009:pp 345–79. Springer.
35.
• Osherov N, Ben-Ami R. Modulation of host angiogenesis as a microbial survival strategy and therapeutic target. PLoS Pathog. 2016;12(4):e1005479. This review summarizes the emerging roles of vasculopathy and angiogenesis in the pathogenesis of invasive aspergillosis. CrossRefPubMedPubMedCentral
36.
Gregg KS, Kauffman CA. Invasive aspergillosis: epidemiology, clinical aspects, and treatment. Semin Respir Crit Care med. 2015;36(5):662–72.CrossRefPubMed
37.
Samanta P, Singh N. Complications of invasive mycoses in organ transplant recipients. Expert review of anti-infective therapy. 2016.
38.
Segal BH, Bow EJ, Menichetti F. Fungal infections in nontransplant patients with hematologic malignancies. Infect dis Clin N am. 2002;16(4):935–64. vii CrossRef
39.
•• Papadopoulou A, Kaloyannidis P, Yannaki E, Cruz CR. Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: progress and challenges. Crit rev Oncol Hematol. 2016;98:62–72. This review highlights the recent advances and the critical issues involved in development and protocol design of Aspergillus-specific T cell immunotherapy. CrossRefPubMed
40.
Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009;44(6):361–70.CrossRefPubMed
41.
Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect dis. 2009;48(3):265–73.CrossRefPubMed
42.
Neofytos D, Treadway S, Ostrander D, Alonso CD, Dierberg KL, Nussenblatt V, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect dis. 2013;15(3):233–42.CrossRefPubMedPubMedCentral
43.
Nucci M, Garnica M, Gloria AB, Lehugeur DS, Dias VC, Palma LC, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19(8):745–51.CrossRefPubMed
44.
Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect dis. 2010;50(8):1091–100.CrossRefPubMed
45.
Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.CrossRefPubMed
46.
Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect dis. 2002;34(7):909–17.CrossRefPubMed
47.
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50(4):476–82.CrossRefPubMedPubMedCentral
48.
49.
50.
Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J med. 2014;370(5):421–32.CrossRefPubMed
51.
Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J med. 2008;359(17):1766–77.CrossRefPubMedPubMedCentral
52.
Chai LY, de Boer MG, van der Velden WJ, Plantinga TS, van Spriel AB, Jacobs C, et al. The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect dis. 2011;203(5):736–43.CrossRefPubMedPubMedCentral
53.
Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect dis. 2010;50(8):1101–11.CrossRefPubMed
54.
•• Lopez-Medrano F, Fernandez-Ruiz M, Silva JT, Carver PL, van Delden C, Merino E, et al. Clinical presentation and determinants of mortality of invasive pulmonary aspergillosis in kidney transplant recipients: a multinational cohort study. Am J Transplant. 2016. This multicenter study shows that the combination antifungal therapy has no mortality benefit for kidney transplant patients with invasive aspergillosis.
55.
Lopez-Medrano F, Silva JT, Fernandez-Ruiz M, Carver PL, van Delden C, Merino E, et al. Risk factors associated with early invasive pulmonary aspergillosis in kidney transplant recipients: results from a multinational matched case-control study. Am J Transplant. 2016;16(7):2148–57.CrossRefPubMed
56.
Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect dis. 2005;41(1):52–9.CrossRefPubMed
57.
Singh N, Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect dis. 2003;36(1):46–52.CrossRefPubMed
58.
Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect. 2011;17(12):1882–9.CrossRefPubMed
59.
Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43(Suppl 1):S49–58.CrossRefPubMed
60.
• Bonnal C, Leleu C, Brugiere O, Chochillon C, Porcher R, Boelle PY, et al. Relationship between fungal colonisation of the respiratory tract in lung transplant recipients and fungal contamination of the hospital environment. PLoS One. 2015;10(12):e0144044. This prospective study shows a significant association between fungal contamination of the patient’s room and aspergillus respiratory colonization of lung transplant patients. CrossRefPubMedPubMedCentral
61.
Iversen M, Burton CM, Vand S, Skovfoged L, Carlsen J, Milman N, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect dis. 2007;26(12):879–86.CrossRefPubMed
62.
• Weigt SS, Copeland CA, Derhovanessian A, Shino MY, Davis WA, Snyder LD, et al. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant. 2013;13(4):919–27. This study shows that colonization of the lung allograft with small conidia Aspergillus species, but not large conidia species, is associated with an increased risk of bronchiolitis obliterans syndrome and suggests that prospective evaluation of strategies to prevent Aspergillus colonization of the airways is warranted. CrossRefPubMedPubMedCentral
63.
Weigt SS, Elashoff RM, Huang C, Ardehali A, Gregson AL, Kubak B, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009;9(8):1903–11.CrossRefPubMedPubMedCentral
64.
Garantziotis S, Palmer SM. An unwelcome guest: Aspergillus colonization in lung transplantation and its association with bronchiolitis obliterans syndrome. Am J Transplant. 2009;9(8):1705–6.CrossRefPubMedPubMedCentral
65.
Husain S, Paterson DL, Studer S, Pilewski J, Crespo M, Zaldonis D, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6(12):3008–16.CrossRefPubMed
66.
Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect dis. 2010;12(3):220–9.CrossRefPubMed
67.
Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect dis. 2006;19(4):365–70.CrossRefPubMed
68.
Munoz P, Ceron I, Valerio M, Palomo J, Villa A, Eworo A, et al. Invasive aspergillosis among heart transplant recipients: a 24-year perspective. J Heart Lung Transplant. 2014;33(3):278–88.CrossRefPubMed
69.
Munoz P, Alcala L, Sanchez Conde M, Palomo J, Yanez J, Pelaez T, et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation. 2003;75(3):326–9.CrossRefPubMed
70.
Righi E, Ivaldi F, Carnelutti A, Tomkova L, Villa G, Sartor A, et al. Immunologic and pharmacologic aspects in an elderly recipient of liver transplant with pulmonary aspergillosis and multiple comorbidities. Exp Clin Transplant. 2016;14(5):567–70.PubMed
71.
Singh N, Husain S, Practice ASTIDCo. Aspergillosis in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):228–41.CrossRefPubMed
72.
Fortun J, Martin-Davila P, Moreno S, De Vicente E, Nuno J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8(11):1065–70.CrossRefPubMed
73.
Brown RS Jr, Lake JR, Katzman BA, Ascher NL, Somberg KA, Emond JC, et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation. 1996;61(4):666–9.CrossRefPubMed
74.
Altiparmak MR, Apaydin S, Trablus S, Serdengecti K, Ataman R, Ozturk R, et al. Systemic fungal infections after renal transplantation. Scand J Infect dis. 2002;34(4):284–8.CrossRefPubMed
75.
Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun. 2005;73(1):494–503.CrossRefPubMedPubMedCentral
76.
Stergiopoulou T, Meletiadis J, Roilides E, Kleiner DE, Schaufele R, Roden M, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol. 2007;127(3):349–55.CrossRefPubMed
77.
Berenguer J, Allende MC, Lee JW, Garrett K, Lyman C, Ali NM, et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care med. 1995;152(3):1079–86.CrossRefPubMed
78.
Duong M, Ouellet N, Simard M, Bergeron Y, Olivier M, Bergeron MG. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect dis. 1998;178(5):1472–82.CrossRefPubMed
79.
Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect dis. 2007;44(3):373–9.CrossRefPubMed
80.
Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect dis. 2011;52(9):1144–55.CrossRefPubMedPubMedCentral
81.
Park YS, Seo JB, Lee YK, Do KH, Lee JS, Song JW, et al. Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin Radiol. 2008;63(6):673–80.CrossRefPubMed
82.
Gaspar BL, Agarwal R, Gupta K, Shivaprakash MR. Aspergillus pseudomembranous tracheobronchitis in an immunocompetent individual: a diagnostic conundrum with therapeutic challenge. Lung India. 2016;33(5):550–2.CrossRefPubMedPubMedCentral
83.
84.
Geltner C, Lass-Florl C. Invasive pulmonary aspergillosis in organ transplants—focus on lung transplants. Respir Investig. 2016;54(2):76–84.CrossRefPubMed
85.
Fernandez-Ruiz M, Silva JT, San-Juan R, de Dios B, Garcia-Lujan R, Lopez-Medrano F, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91(5):261–73.CrossRef
86.
• Haidar G, Crespo M, Maximous S, Lendermon E, Clancy CJ, Nguyen MH. Invasive tracheobronchial aspergillosis in a lung transplant recipient receiving belatacept as salvage maintenance immunosuppression: a case report. Transplant Proc. 2016;48(1):275–8. This is an interesting case report describing belatacept as a potential risk factor for invasive aspergillosis. CrossRefPubMed
87.
Fitzsimons EJ, Aris R, Patterson R. Recurrence of allergic bronchopulmonary aspergillosis in the posttransplant lungs of a cystic fibrosis patient. Chest. 1997;112(1):281–2.CrossRefPubMed
88.
Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant. 2002;21(11):1237–41.CrossRefPubMed
89.
Cerceo E, Kotloff RM, Hadjiliadis D, Ahya VN, Pochettino A, Gillespie C, et al. Central airways obstruction due to Aspergillus fumigatus after lung transplantation. J Heart Lung Transplant. 2009;28(5):515–9.CrossRefPubMedPubMedCentral
90.
Verleden GM, Dupont LJ, Van Raemdonck DE. ABPA: does it really exist after lung transplantation? J Heart Lung Transplant. 2009;28(11):1239.CrossRefPubMed
Metadata
Title
Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients
Authors
Palash Samanta
M. Hong Nguyen
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 4/2017
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-017-0278-5

Other articles of this Issue 4/2017

Current Fungal Infection Reports 4/2017 Go to the issue

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Heteroresistance to Fluconazol in Clinical and Environmental Brazilian Strains of Cryptococcus neoformans/C. gattii Species Complex

Current Management of Fungal Infections (M Miceli, Section Editor)

The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach

Erratum

Erratum to: Harnessing Whole Genome Sequencing in Medical Mycology

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Cryptococcus neoformans Epidemiological Cutoff Values

Fungal Genomics and Pathogenesis (Shmuel Shoham, Section Editor)

What Is New? Recent Knowledge on Fungal Extracellular Vesicles

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits